依普利酮对高血压有多大的效果呢？

It is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the US National Food and Drug Administration in 2002. Eplerenone is mainly used for the treatment of congestive heart failure and hypertension after acute myocardial infarction.

The common dosage of eplerenone for adults with hypertension. Eplerenone can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg, taken orally, once a day. Maintenance dose: 50 mg, taken orally, 1-2 times a day. Maximum dose: 100 mg/day. Obvious antihypertensive effects appear within four weeks of medication. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

How effective is eplerenone against high blood pressure?

For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction. The combined use of standard treatment drugs for the treatment of heart failure after acute myocardial infarction can reduce the overall mortality rate in the treatment group by 15% ( P=0.008); eplerenone and enalapril are equally effective in reversing left ventricular hypertrophy and hypertension, with less cough side effects, and the combined effect is more obvious; there are few adverse reactions, except for the adverse reactions of increased blood potassium, other adverse reactions are no different from the placebo group; there are almost no sex hormone-related side effects of spironolactone.

The FDA (U.S. Food and Drug Administration) has approved eplerenone for use in stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and congestive heart failure after acute myocardial infarction (MI) to improve survival rates. Eplerenone is the first aldosterone receptor blocker approved for this indication. The FDA approval was based on the results of the EPHESUS (Efficacy and Survival in Heart Failure After Acute Myocardial Infarction Study) trial.